

# Jordi Rio

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9358280/publications.pdf>

Version: 2024-02-01

121  
papers

6,318  
citations

66234

42  
h-index

74018

75  
g-index

132  
all docs

132  
docs citations

132  
times ranked

5645  
citing authors

#	ARTICLE	IF	CITATIONS
1	Menopause does not modify disability trajectories in a longitudinal cohort of women with clinically isolated syndrome and multiple sclerosis followed from disease onset. <i>European Journal of Neurology</i> , 2022, 29, 1075-1081.	1.7	16
2	Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients. <i>Journal of Neurology</i> , 2022, 269, 452-459.	1.8	10
3	Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 950-957.	1.4	7
4	Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre. <i>Journal of Neurology</i> , 2022, 269, 1764-1772.	1.8	5
5	Herpes simplex encephalitis in the context of immune checkpoint inhibitors: a complex interplay. <i>Acta Neurologica Belgica</i> , 2022, 122, 823-825.	0.5	3
6	Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, e1143.	3.1	17
7	Spinal cord grey matter atrophy in Multiple Sclerosis clinical practice. <i>Neuroscience Informatics</i> , 2022, 2, 100071.	2.8	1
8	Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103805.	0.9	2
9	Serum neurofilament light chain levels predict long-term disability progression in patients with progressive multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 732-740.	0.9	8
10	Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1138-1145.	1.4	11
11	Immunotherapy for people with clinically isolated syndrome or relapsing-remitting multiple sclerosis: treatment response by demographic, clinical, and biomarker subgroups (PROMISE) – a systematic review protocol. <i>Systematic Reviews</i> , 2022, 11, .	2.5	0
12	Adding brain volume measures into response criteria in multiple sclerosis: the R <sup>2</sup> -4 score. <i>Neuroradiology</i> , 2021, 63, 1031-1041.	1.1	2
13	COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response. <i>European Journal of Neurology</i> , 2021, 28, 3384-3395.	1.7	111
14	The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia. <i>Multiple Sclerosis Journal</i> , 2021, 27, 913-921.	1.4	20
15	Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	3.1	12
16	Scoring the 10-year risk of ambulatory disability in multiple sclerosis: the RoAD score. <i>European Journal of Neurology</i> , 2021, 28, 2533-2542.	1.7	16
17	Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome. <i>Neurology</i> , 2021, 97, e1641-e1652.	1.5	35
18	Optic Nerve Topography in Multiple Sclerosis Diagnosis. <i>Neurology</i> , 2021, 96, e482-e490.	1.5	32

#	ARTICLE	IF	CITATIONS
19	A pharmacogenetic study implicates NINJ2 in the response to Interferon- $\beta$ in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1074-1082.	1.4	5
20	The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1658-1669.	1.4	41
21	MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. <i>Nature Reviews Neurology</i> , 2020, 16, 171-182.	4.9	150
22	Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis. <i>Neurology</i> , 2019, 92, e1507-e1516.	1.5	49
23	Simultaneous CMV and <i>Listeria</i> infection following alemtuzumab treatment for multiple sclerosis. <i>Neurology</i> , 2019, 92, 296-298.	1.5	15
24	Unraveling treatment response in multiple sclerosis. <i>Neurology</i> , 2019, 92, 180-192.	1.5	88
25	Clinical commentary on "Two cases of anaphylactic shock by methylprednisolone in neuromyelitis optica". <i>Multiple Sclerosis Journal</i> , 2018, 24, 1516-1517.	1.4	0
26	The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. <i>Brain</i> , 2018, 141, 1075-1084.	3.7	98
27	Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. <i>Brain</i> , 2018, 141, 1085-1093.	3.7	115
28	Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor. <i>Multiple Sclerosis Journal</i> , 2018, 24, 301-312.	1.4	79
29	Disability progression markers over 6-12 years in interferon- $\beta$ -treated multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2018, 24, 322-330.	1.4	60
30	Varicella-zoster meningovascularitis in a multiple sclerosis patient treated with natalizumab. <i>Multiple Sclerosis Journal</i> , 2018, 24, 358-360.	1.4	17
31	Blood lymphocyte subsets identify optimal responders to IFN-beta in MS. <i>Journal of Neurology</i> , 2018, 265, 24-31.	1.8	11
32	NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1507-1510.	1.4	11
33	Circulating EZH2-positive T cells are decreased in multiple sclerosis patients. <i>Journal of Neuroinflammation</i> , 2018, 15, 296.	3.1	7
34	Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2017, 303, 62-65.	1.1	16
35	MR Imaging in Monitoring and Predicting Treatment Response in Multiple Sclerosis. <i>Neuroimaging Clinics of North America</i> , 2017, 27, 277-287.	0.5	20
36	Lesion topographies in multiple sclerosis diagnosis. <i>Neurology</i> , 2017, 89, 2351-2356.	1.5	27

#	ARTICLE	IF	CITATIONS
37	Grey matter atrophy is associated with disability increase in natalizumab-treated patients. <i>Multiple Sclerosis Journal</i> , 2017, 23, 556-566.	1.4	21
38	Neurofilament light chain level is a weak risk factor for the development of MS. <i>Neurology</i> , 2016, 87, 1076-1084.	1.5	85
39	Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis. <i>Neurology</i> , 2016, 87, 1368-1374.	1.5	42
40	Assessing response to interferon- $\beta$ in a multicenter dataset of patients with MS. <i>Neurology</i> , 2016, 87, 134-140.	1.5	98
41	Brain Volume Loss During the First Year of Interferon- $\beta$ Treatment in Multiple Sclerosis: Baseline Inflammation and Regional Brain Volume Dynamics. <i>Journal of Neuroimaging</i> , 2016, 26, 532-538.	1.0	21
42	Short-term suboptimal response criteria for predicting long-term non-response to first-line disease modifying therapies in multiple sclerosis: A systematic review and meta-analysis. <i>Journal of the Neurological Sciences</i> , 2016, 361, 158-167.	0.3	20
43	MRI phenotypes with high neurodegeneration are associated with peripheral blood B-cell changes. <i>Human Molecular Genetics</i> , 2016, 25, 308-316.	1.4	31
44	A 10-year follow-up of the European multicenter trial of interferon $\beta$ -1b in secondary-progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 533-543.	1.4	24
45	Pharmacogenomic study in patients with multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e154.	3.1	19
46	Should we systematically test patients with clinically isolated syndrome for auto-antibodies?. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1802-1810.	1.4	10
47	Predictive value of early brain atrophy on response in patients treated with interferon $\beta$ . <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e132.	3.1	28
48	NLRP3 inflammasome is associated with the response to IFN- $\beta$ in patients with multiple sclerosis. <i>Brain</i> , 2015, 138, 644-652.	3.7	93
49	Defining high, medium and low impact prognostic factors for developing multiple sclerosis. <i>Brain</i> , 2015, 138, 1863-1874.	3.7	403
50	Any evident MRI T2 lesion activity should guide change of therapy in multiple sclerosis: No. <i>Multiple Sclerosis Journal</i> , 2015, 21, 132-133.	1.4	7
51	Peripheral blood non-MAIT CD8+CD161hi cells are decreased in relapsing-remitting multiple sclerosis patients treated with interferon beta. <i>Journal of Neuroimmunology</i> , 2015, 288, 98-101.	1.1	12
52	Significant clinical worsening after natalizumab withdrawal: Predictive factors. <i>Multiple Sclerosis Journal</i> , 2015, 21, 780-785.	1.4	43
53	Brain atrophy in natalizumab-treated patients: A 3-year follow-up. <i>Multiple Sclerosis Journal</i> , 2015, 21, 749-756.	1.4	51
54	Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1602-1608.	1.4	36

#	ARTICLE	IF	CITATIONS
55	Activation-induced cell death in T lymphocytes from multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2014, 272, 51-55.	1.1	8
56	HLA alleles as biomarkers of high-titre neutralising antibodies to interferon- $\beta$ therapy in multiple sclerosis. <i>Journal of Medical Genetics</i> , 2014, 51, 395-400.	1.5	19
57	Up-regulation of inducible heat shock protein-70 expression in multiple sclerosis patients. <i>Autoimmunity</i> , 2014, 47, 127-133.	1.2	17
58	Analysis of prognostic factors associated with longitudinally extensive transverse myelitis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 742-748.	1.4	35
59	Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1175-1181.	1.4	93
60	Treatment with interferon-beta does not induce anti-nuclear and anti-neuronal serum autoantibodies in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2013, 255, 102-104.	1.1	1
61	Roles of the ubiquitin peptidase <i>USP18</i> in multiple sclerosis and the response to interferon- $\beta$ treatment. <i>European Journal of Neurology</i> , 2013, 20, 1390-1397.	1.7	32
62	Cellular immune responses in multiple sclerosis patients treated with interferon-beta. <i>Clinical and Experimental Immunology</i> , 2013, 171, 243-246.	1.1	5
63	Clinical impact of early brain atrophy in clinically isolated syndromes. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1878-1886.	1.4	85
64	Scoring treatment response in patients with relapsing multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 605-612.	1.4	227
65	Baseline Gene Expression Signatures in Monocytes from Multiple Sclerosis Patients Treated with Interferon-beta. <i>PLoS ONE</i> , 2013, 8, e60994.	1.1	27
66	Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment. <i>PLoS ONE</i> , 2013, 8, e82796.	1.1	23
67	EBV-specific immune responses in patients with multiple sclerosis responding to IFN $\beta$ therapy. <i>Multiple Sclerosis Journal</i> , 2012, 18, 605-609.	1.4	20
68	Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1193-1196.	1.4	19
69	Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response. <i>European Journal of Neurology</i> , 2012, 19, 899-904.	1.7	55
70	Multiple sclerosis: current treatment algorithms. <i>Current Opinion in Neurology</i> , 2011, 24, 230-237.	1.8	65
71	IL28B polymorphisms are not associated with the response to interferon-beta in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2011, 239, 101-104.	1.1	18
72	Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis. <i>Clinical Immunology</i> , 2011, 141, 348-356.	1.4	72

#	ARTICLE	IF	CITATIONS
73	Implication of the toll-like receptor 4 pathway in the response to interferon- $\beta$ in multiple sclerosis. <i>Annals of Neurology</i> , 2011, 70, 634-645.	2.8	35
74	Interferon Beta-1b for the Treatment of Primary Progressive Multiple Sclerosis. <i>Archives of Neurology</i> , 2011, 68, 1421.	4.9	44
75	Search for Specific Biomarkers of IFN- $\beta$ Bioactivity in Patients with Multiple Sclerosis. <i>PLoS ONE</i> , 2011, 6, e23634.	1.1	45
76	Clinical features of CIS of the brainstem/cerebellum of the kind seen in MS. <i>Journal of Neurology</i> , 2010, 257, 742-746.	1.8	19
77	Do multimodal evoked potentials add information to MRI in clinically isolated syndromes?. <i>Multiple Sclerosis Journal</i> , 2010, 16, 55-61.	1.4	54
78	Measures in the first year of therapy predict the response to interferon- $\beta$ in MS. <i>Multiple Sclerosis Journal</i> , 2009, 15, 848-853.	1.4	215
79	Predicting responders to therapies for multiple sclerosis. <i>Nature Reviews Neurology</i> , 2009, 5, 553-560.	4.9	114
80	A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 1195-1205.	1.4	95
81	A type I interferon signature in monocytes is associated with poor response to interferon- $\beta$ in multiple sclerosis. <i>Brain</i> , 2009, 132, 3353-3365.	3.7	186
82	Genome-wide Scan of 500,000 Single-Nucleotide Polymorphisms Among Responders and Nonresponders to Interferon Beta Therapy in Multiple Sclerosis. <i>Archives of Neurology</i> , 2009, 66, 972-8.	4.9	104
83	HLA class I and II alleles and response to treatment with interferon-beta in relapsing-remitting multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2009, 210, 116-119.	1.1	33
84	Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis. <i>Clinical Immunology</i> , 2009, 130, 145-150.	1.4	41
85	Plasma chitotriosidase activity in multiple sclerosis. <i>Clinical Immunology</i> , 2009, 131, 216-222.	1.4	27
86	Plasma levels of 15dPGJ <sub>2</sub> are not altered in multiple sclerosis. <i>European Journal of Neurology</i> , 2009, 16, 1197-1201.	1.7	7
87	The basal ganglia: a substrate for fatigue in multiple sclerosis. <i>Neuroradiology</i> , 2008, 50, 17-23.	1.1	91
88	Induction of serum soluble tumor necrosis factor receptor II (sTNF-RII) and interleukin-1 receptor antagonist (IL-1ra) by interferon beta-1b in patients with progressive multiple sclerosis. <i>Journal of Neurology</i> , 2008, 255, 1136-1141.	1.8	23
89	Relationship between MRI lesion activity and response to IFN- $\beta$ in relapsing-remitting multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2008, 14, 479-484.	1.4	104
90	Very early scans for demonstrating dissemination in time in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 631-635.	1.4	17

#	ARTICLE	IF	CITATIONS
91	Identification of a Novel Risk Locus for Multiple Sclerosis at 13q31.3 by a Pooled Genome-Wide Scan of 500,000 Single Nucleotide Polymorphisms. PLoS ONE, 2008, 3, e3490.	1.1	99
92	Polyregional and hemispheric syndromes: a study of these uncommon first attacks in a CIS cohort. Multiple Sclerosis Journal, 2007, 13, 731-736.	1.4	6
93	Interferon beta in secondary progressive multiple sclerosis. Journal of Neurology, 2007, 254, 849-853.	1.8	4
94	Interferons and cognition. Journal of the Neurological Sciences, 2006, 245, 137-140.	0.3	18
95	Reply to D. S. Goodin. Journal of Neurology, 2006, 253, 949-949.	1.8	0
96	Fatigue in multiple sclerosis persists over time. Journal of Neurology, 2006, 253, 1466-1470.	1.8	80
97	Defining the response to interferon- $\beta$ in relapsing-remitting multiple sclerosis patients. Annals of Neurology, 2006, 59, 344-352.	2.8	295
98	Fatigue in progressive multiple sclerosis is associated with low levels of dehydroepiandrosterone. Multiple Sclerosis Journal, 2006, 12, 487-494.	1.4	67
99	Plasma osteopontin levels in multiple sclerosis. Journal of Neuroimmunology, 2005, 158, 231-239.	1.1	171
100	Is optic neuritis more benign than other first attacks in multiple sclerosis?. Annals of Neurology, 2005, 57, 210-215.	2.8	108
101	Interferon beta in relapsing-remitting multiple sclerosis. Journal of Neurology, 2005, 252, 795-800.	1.8	59
102	Does the Modified Fatigue Impact Scale offer a more comprehensive assessment of fatigue in MS?. Multiple Sclerosis Journal, 2005, 11, 198-202.	1.4	243
103	Interferon- $\beta$ in the treatment of multiple sclerosis. Expert Opinion on Pharmacotherapy, 2005, 6, 2877-2886.	0.9	14
104	Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis. Multiple Sclerosis Journal, 2005, 11, 306-309.	1.4	184
105	IFN- $\beta$ treatment modulates the CD28/CTLA-4-mediated pathway for IL-2 production in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2004, 10, 630-635.	1.4	9
106	Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis. Multiple Sclerosis Journal, 2004, 10, 413-416.	1.4	30
107	Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology, 2004, 62, 1653-1653.	1.5	26
108	Specificity of Barkhof Criteria in Predicting Conversion to Multiple Sclerosis When Applied to Clinically Isolated Brainstem Syndromes. Archives of Neurology, 2004, 61, 222.	4.9	32

#	ARTICLE	IF	CITATIONS
109	Transcription-Based Prediction of Response to IFN $\beta$ Using Supervised Computational Methods. PLoS Biology, 2004, 3, e2.	2.6	144
110	Serial gadolinium-enhanced MRI in acute attack of multiple sclerosis treated with plasma exchange. Journal of Neurology, 2003, 250, 243-244.	1.8	4
111	Clinically definite multiple sclerosis after radiological Schilder-like onset. Journal of Neurology, 2003, 250, 871-873.	1.8	5
112	Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis. Genes and Immunity, 2003, 4, 147-152.	2.2	77
113	Myelopathy in seronegative Sjögren syndrome and/or primary progressive multiple sclerosis. Multiple Sclerosis Journal, 2003, 9, 256-259.	1.4	22
114	Unconventional therapy in multiple sclerosis. Multiple Sclerosis Journal, 2003, 9, 320-322.	1.4	18
115	Serial immunoprecipitation assays for interferon- $\gamma$ -(IFN)-beta antibodies in multiple sclerosis patients. European Cytokine Network, 2003, 14, 154-7.	1.1	9
116	The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon- $\beta$ . Journal of Neuroimmunology, 2002, 130, 194-201.	1.1	78
117	Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon $\beta$ : Implications for clinical trials. Annals of Neurology, 2002, 52, 400-406.	2.8	114
118	Serial diffusion-weighted MR imaging and proton MR spectroscopy of acute large demyelinating brain lesions: case report. American Journal of Neuroradiology, 2002, 23, 989-94.	1.2	56
119	Proton magnetic resonance spectroscopy in primary and secondary progressive multiple sclerosis. NMR in Biomedicine, 2000, 13, 57-63.	1.6	41
120	Asterix associated with anatomic cerebral lesions: a study of 45 cases. Acta Neurologica Scandinavica, 1995, 91, 377-381.	1.0	23
121	Serum Homocysteine Levels in Multiple Sclerosis. Archives of Neurology, 1994, 51, 1181-1181.	4.9	23